GlassScriptPhysician profile
Richard Matthew Buurman
NPI 1467544148
$4,913.20
in general payments reported to CMS, 2019-2025
42 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $533 · 2021: $888 · 2022: $684 · 2023: $496 · 2024: $868 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,389.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,323.32 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $365.74 | 2019-2025 | Repatha, Krystexxa, Otezla |
| Lilly USA, LLC | $318.38 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $292.49 | 2024-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $202.83 | 2019-2025 | |
| Abbott Laboratories | $190.08 | 2022-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $187.08 | 2022-2025 | |
| Astellas Pharma US INC | $185.11 | 2019-2025 | Veozah |
| Pfizer INC. | $180.79 | 2019-2025 | |
| Abbvie INC. | $149.96 | 2021-2025 | Ubrelvy, Vraylar |
| Exact Sciences Corporation | $114.49 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $112.84 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $99.72 | 2019-2022 | |
| Glaxosmithkline, LLC. | $90.30 | 2020-2023 | Arexvy, Trelegy Ellipta |
| Eisai INC. | $88.34 | 2021-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Buurman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.